How to Help Your Patients Find Temozolomide in Stock: A Provider's Guide

Temozolomide is the cornerstone chemotherapy for glioblastoma (GBM) — and the last thing a patient in active treatment should have to worry about is whether they can fill their prescription. Yet the specialty drug distribution system regularly creates access barriers that result in missed or delayed treatment cycles. This guide gives oncology providers and their care teams a concrete framework for minimizing those gaps.

Why Access Barriers Occur Even When Supply Is Adequate

Temozolomide is not currently in a national shortage. Multiple generic manufacturers produce it. But patients frequently experience access problems for the following reasons:

• Retail pharmacies don't stock it: Low patient volume means most community pharmacies don't order temozolomide routinely.
• Multi-strength prescriptions: BSA-based dosing often requires 2–3 different capsule strengths per cycle (e.g., 100 mg + 20 mg + 5 mg). A pharmacy may stock one strength but not another.
• Insurance prior authorization delays: PA processing takes 2–7 business days. Submitting late can push a patient past their cycle start date.
• Patients don't know where to look: Patients unfamiliar with specialty pharmacy systems often call regular pharmacies first and give up after a few rejections.

Step 1: Route the Prescription to a Specialty Pharmacy from Day One

The single highest-impact step your practice can take is establishing a standard workflow that routes new temozolomide prescriptions directly to a specialty pharmacy — never to a retail chain. Establish preferred specialty pharmacy partnerships: CVS Specialty, Accredo, BriovaRx, and your cancer center's in-house pharmacy are all reliable dispensers of temozolomide.

Step 2: Submit Prior Authorization 10 Days Before Each Cycle

Build PA submission into your end-of-cycle workflow. At the final clinic visit before a new cycle begins, have your team initiate PA if it is due for renewal. A standard template for the PA documentation — including the diagnosis (GBM or anaplastic astrocytoma), prior treatment, and cycle number — speeds the process significantly. Document MGMT methylation status, if relevant, as some payers require it.

Step 3: Write Clear Multi-Strength Prescriptions

Patients are often prescribed temozolomide doses that cannot be filled with a single capsule strength. Explicitly listing all required strengths on one prescription — for example, "temozolomide 100 mg × 2 capsules + temozolomide 20 mg × 1 capsule + temozolomide 5 mg × 3 capsules, Days 1–5 of 28-day cycle" — reduces pharmacy confusion and prevents partial dispensing.

Step 4: Assign a Pharmacy Liaison or Nurse Navigator to Each Patient

Practices with oncology-dedicated nurse navigators or pharmacy liaisons experience far fewer treatment delays. Assigning a point person to confirm fill status 5 days before each cycle start — and to intervene when a pharmacy reports a stock issue — catches problems before they become delays. Document this contact in the patient's chart.

Step 5: Recommend medfinder for Patients Who Need Help Locally

When a patient is struggling to find a specific temozolomide strength at a pharmacy near them, medfinder can help. medfinder calls pharmacies near the patient's location to check which ones have the medication in stock and can fill the prescription. Results are sent via text. This eliminates the time-consuming process of patients calling pharmacy after pharmacy on their own — particularly valuable for patients who may be fatigued or cognitively impaired due to their brain tumor.

Step 6: Develop a Treatment Interruption Protocol

Despite best efforts, occasional fill delays will occur. Have a documented protocol that addresses: What constitutes an acceptable delay? (Most oncologists advise that a 1–2 day delay during maintenance is less critical than during the concurrent RT phase.) Who contacts the patient? What is the backup pharmacy? When do you consider an alternative chemotherapy? Documenting this process ensures consistent responses across your care team.

Patient Education Points: What to Tell Your Patients

Coach your patients with these key points at each cycle:

• Start looking for your medication 7–10 days before your cycle begins — not the day before.
• Know the exact capsule strength(s) you need and the quantity of each.
• Do not open, crush, or chew capsules — the powder is a hazardous substance and should not contact skin, eyes, or mucous membranes.
• Call your care team if you cannot fill your prescription — do not skip doses on your own.

Summary Checklist for Your Practice

• Establish specialty pharmacy routing as the default for all temozolomide prescriptions
• Submit PA 10 days before each new cycle
• Write prescriptions with all required strengths explicitly listed
• Assign a pharmacy liaison to check fill status 5 days before each cycle
• Recommend medfinder.com for patients who need help locating their specific capsule strength locally
• Have a documented protocol for what to do when a fill is delayed

For the broader shortage context, see: Temozolomide Shortage: What Providers Need to Know in 2026.